Benchmark analyst Robert Wasserman downgraded Emergent BioSolutions to Hold from Buy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions cuts FY22 revenue view $1.05B-$1.1B from $1.15B-$1.25B
- Emergent BioSolutions reports Q3 adjusted EPS ($1.27), consensus (6c)
- Emergent BioSolutions Reports Financial Results For Third Quarter 2022
- Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
- Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022